Frontlight ResearchEarly access
Trial site
University of Chicago Hospital
- 9running trials
- 5closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Conditions
- Acute myeloid leukaemia2 trials
- Chronic myeloid leukaemia2 trials
- High blood pressure2 trials
- Lung cancer2 trials
- Myeloproliferative neoplasms2 trials
- Aortic aneurysm1 trial
- Atrial fibrillation1 trial
- Bladder cancer1 trial
- Cervical cancer1 trial
- Gastric and oesophageal cancer1 trial
- Head and neck cancer1 trial
- Liver and biliary tract cancer1 trial
- and 8 more
- Phase
- Phase 34 trials
- Phase 13 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Recruiting5 trials
- Active, not recruiting4 trials
- Completed3 trials
- Terminated2 trials
- Lead sponsor
- University of Chicago4 trials
- Eli Lilly and Company3 trials
- Boston Scientific Corporation2 trials
- Novartis Pharmaceuticals2 trials
- Amgen1 trial
- and 2 more
Running trials
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer2 recruiting
- Aortic aneurysm1 recruiting
- Bladder cancer1 recruiting
- Cervical cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Head and neck cancer1 recruiting
- High blood pressure1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Ovarian cancer1 recruiting
- Pancreatic cancer1 recruiting
- Prostate cancer1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Terminated
Completed
Completed
Completed
Terminated
Site data: ClinicalTrials.govUpdated 18 Nov 2026